Financials
Financial year 2025
Worth noting
- More debts than assets in the latest financial year.
- Little cash and receivables against the short-term debts.
Revenue
€ 30,000
Profit
Growing€ 313,335
▲ 662% vs 2024
Debts
High€ 5.3 million
▼ 1% vs 2024
Aelin Therapeutics from Brugge, company number BE0685688842, closed financial year 2025 with a result of € 313,335 after tax. For that financial year Aelin Therapeutics recorded revenue of € 30,000 and equity of € -3.2 million. Compared with financial year 2024, the result moved from € 41,100 to € 313,335. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 10, 2026.
What happened at Aelin Therapeutics?
What happened at Aelin Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 313,335 (▲ 662% vs 2024). filed late Source: NBB ↗
- Dave Pardo became a director. NBB
- Pieter Van Aerschot became a director. NBB
- New establishment in Gent. KBO
- New establishment in Leuven. KBO
- Start of the company according to the CBE. KBO
In short
From € 7.3 million loss in 2022 to € 313,335 profit in 2025.
Paid € 942,627 in corporate taxes since 2022.
Best year ever: 2023, with € 411,634 profit.
A new publication or filing at Aelin Therapeutics? We notify you, reason included.
Follow Aelin TherapeuticsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind Aelin Therapeutics are Dave Pardo and Pieter Van Aerschot. The shares are held by LSP V Coöperatieve LLA (30.9%), Fund+ NV (19.9%), Boehringer Ingelheim Venture Fund GmbH (16.9%), BFV NV (16%), Vlaams Interuniversitair Instituut voor Biotechnologie VZW (12%) and PMV NV (4%).
Directors
According to the 2025 annual accounts
since 2023
since 2023
Shareholders
LSP V Coöperatieve LLA
30.9%
19.9%
16%
4%
Novartis Bioventures Ltd
0.3%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Lieven Bauwensstraat 20
8200 Brugge
Gaston Geenslaan 1
3001 Leuven
Active since 6 December 2017
Technologiepark-Zwijnaarde 73A
9052 Gent
Active since 15 January 2021
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 21 companies are registered at this address.
Koninklijke Vlaamse Krachtbalfederatie
BEDRIJVENCENTRUM REGIO BRUGGE
€ 117,037 gross margin · 2025
FLIN same network
€ 289,646 gross margin · 2025
BOUWONDERNEMING SANDERS
DANSPLATOO
+16 more
Details
- Company number
- 0685.688.842
- VAT number
- BE 0685.688.842
- Registered office
- Lieven Bauwensstraat 20, 8200 Brugge
- Names & denominations
- Aelin Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Vrijwillige ontbinding – vereffening
- Start date
- 6 December 2017
- Peppol
- Active · Active since 5 Nov 2025
- Activities · NACE
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige gespecialiseerde wetenschappelijke en technische activiteiten
Activiteiten van medische beeldvorming en medische laboratoria
Activiteiten van medische laboratoria